Condition: Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma · Kidney Cancer · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Single arm, single site, open-label Phase II study of the effects of oral olaparib in participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1 criteria.
This description comes directly from the study's public registry record.
Irina Rifkind, RN, MSN · 410-502-2043 · irifkin1@jhmi.edu
Rana Sullivan, RN, BSN · 410-614-6337 · tomalra@jhmi.edu
Always discuss trial participation with your own doctor first.
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03786796